Alzheimer's drug trial failures may be due to second disease : upi

as informed in upi

Alzheimer's drug trial failures may be due to second disease

Alzheimer's drug trial failures may be due to second disease

LEXINGTON, Ky., Oct. 3 (UPI) -- The failure of many Alzheimer's disease drug trials can be traced back to patients having a second dementia-causing ailment, Kentucky University scientists say.To combat the disease, characterized by the buildup of amyloid plaques in the brain, researchers have invested in immunotherapy methods targeting the formation of brain plaques containing amyloid β peptides.However, Kentucky University's Donna Wilcock, PhD, says this approach may prove ineffective for many patients living with the disease.A disease called Vascular Cognitive Impairment and Dementia, or VCID, is typically characterized by an inadequate blood flow to a patient's brain, leading to an increase in memory loss.


not to mention ft

Allergan to buy bowel disease drug from AstraZeneca

Allergan to buy bowel disease drug from AstraZeneca

You have viewed your allowance of free articles.If you wish to view more, click the button below.


moreover from pmlive

AZ licenses inflammatory bowel disease drug to Allergan for $1.52bn

AZ licenses inflammatory bowel disease drug to Allergan for $1.52bn

AstraZeneca's streamlining exercise continues this week with the licensing of mid-stage drug MEDI2070 for Crohn's disease and ulcerative colitis to Allergan.The drug - developed by AZ's Medimmune subsidiary in partnership with with Amgen - lies outside the company's three areas of therapeutic focus - respiratory, cardiovascular and metabolic disease, and cancer.MEDI2070 is an interleukin-23 (IL-23) targeting antibody currently in a phase IIb trial in Crohn's and a phase II trial in ulcerative colitis.Allergan is paying $250m upfront for global rights to MEDI2070, with another $1.27bn on offer if the drug reaches the market in both its indications and achieves certain undisclosed sales targets.